Health knowledge made personal
Join this community!
› Share page:
Search posts:

The U.S. Food and Drug Administr ...

Posted Nov 10 2008 4:22pm

The U.S. Food and Drug Administration announced that it has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.
"In a randomized clinical trial, the group of patients with inoperable hepatocellular carcinoma who received Nexavar survived 2.8 months longer than the group of patients who didn't receive the drug," said Robert Justice, M.D., director of FDA's division of drug oncology products. "This is an important new treatment option for patients who are fighting this very difficult form of cancer."

FDA Approves Nexavar For Patients With Inoperable Liver Cancer

Post a comment
Write a comment: